Alyeska Investment Group
XGN icon

Alyeska Investment Group’s Exagen XGN Stock Holding History

Alyeska Investment Group’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-102,231
Closed -$1.79M – 857
2021
Q1 		$1.79M Buy
+102,231
New +$1.82M 0.02% 489
2019
Q4 		– Sell
-67,771
Closed -$1.05M – 500
2019
Q3 		$1.05M Buy
+67,771
New +$1.09M 0.02% 320

Other funds holding XGN

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Alyeska Investment Group's XGN Position: Q2 2021 in Review

Alyeska Investment Group sold out of Exagen (XGN) in Q2 2021, closing a stake of 102,231 shares — an estimated $1.79M sold.

Alyeska Investment Group first reported a position in XGN in Q3 2019 and held it in 2 quarters. The position peaked at $1.79M in Q1 2021. 54 funds tracked by Wall St. Rank hold XGN as of Q2 2021.

  • Alyeska Investment Group reported no remaining Exagen position as of Q2 2021 after selling out during the quarter.
  • Alyeska Investment Group sold 102,231 Exagen shares in Q2 2021, an estimated $1.79M.
  • Alyeska Investment Group first reported a position in Exagen in Q3 2019 and held it in 2 quarters.
  • Alyeska Investment Group's Exagen position peaked at $1.79M in Q1 2021.
  • 54 funds tracked by Wall St. Rank held Exagen as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.